Without question, some of BioInformant’s most popular content has been our exclusive interviews with stem cell executives and key opinion leaders (KOL). Highlighted below are six of our most popular interviews. Enjoy! [Read more…]
CardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center
In news released today, CardioCell, LLC, announced that a fifth treatment center has been chosen for participation in its Phase II clinical trial that will investigate the use of allogeneic mesenchymal bone marrow cells (aMBMC) in the treatment of non-ischemic heart failure (Study #NCT02467387). Now recruiting patients for this fifth location, the clinical study launched June 2014 and has an estimated end date of April 2017.
To learn more about the announcement, see the full press release below, printed with permission from Marcie Frank, Stemedica’s Vice President, Investor Relations. [Read more…]
Did You Hear About These Stem Cell Events?
The stem cell sector is fueled by innovation and rapid change. To keep you up-to-date, we recently released new coverage of the industry. Check it out and let us know what you think! [Read more…]
What Types of Mesenchymal Stem Cell (MSC) Research Are Getting Funded?
To analyze trends within the mesenchymal stem cell (MSC) industry, it is valuable to consider grant rate data. Previously, the U.S. federal government operated an online tool called CRISP (“Computer Retrieval of Information on Scientific Projects”). It was a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other U.S. research institutions. The database allowed users to search the CRISP interface for grants funding for specific types of scientific research, using text-based search terms.
However, that has since been replaced by RePORTer (Research Portfolio Online Reporting Tools)1, a more powerful database and search tool supported by the U.S. Department of Health and Human Services. RePORTer allows users to search a comprehensive repository of National Institutes of Health (NIH) funded research projects resulting from NIH funding. [Read more…]
No Longer Just for Humans — Cord Blood Banking Now Available to Horses Too
VetiCell, LLC, has announced that it is launching a proactive stem cell storage program for animals, in which it will collect stem cells from the umbilical cord of horses or from the reproductive tissues of dogs following spay or neuter.
VetiCell is a sister company to AlphaCord, a human cord blood bank, with the two companies having the same owner and staff.
Currently, there are a couple companies operating in the veterinary stem cell market that collect stem cells through invasive methods (adipose or bone marrow). However, VetiCell’s new model is to collect veterinary stem cells without surgery from the umbilical cord of horses or from reproductive tissues after canine spay and neuter. These methods require no additional invasive surgery to collect an animal’s stem cells.
Since 2006, BioInformant has been tracking the human stem cell banking market. Initially, the market was focused on the storage of umbilical cord blood, although it has expanded over the past ten years to include the storage of other types of stem cells, including those present within cord tissue, dental pulp, adipose tissue, and more.
With hundreds of human cord blood banks now competing worldwide, it will be interesting to see whether any of them add equine cord blood banking to their portfolio of human stem cell storage services.
- « Previous Page
- 1
- …
- 170
- 171
- 172
- 173
- 174
- …
- 202
- Next Page »